VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP POWDER FOR SOLUTION

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE)

זמין מ:

GENERIC MEDICAL PARTNERS INC

קוד ATC:

J01XA01

INN (שם בינלאומי):

VANCOMYCIN

כמות:

1G

טופס פרצבטיות:

POWDER FOR SOLUTION

הרכב:

VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE) 1G

מסלול נתינה (של תרופות):

INTRAVENOUS

יחידות באריזה:

15G/50G

סוג מרשם:

Prescription

איזור תרפויטי:

GLYCOPEPTIDES

leaflet_short:

Active ingredient group (AIG) number: 0131315009; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2014-12-18

מאפייני מוצר

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP
500 mg and 1 g of Vancomycin (as Vancomycin Hydrochloride)
per vial
Sterile Lyophilized
Powder for Solution
ANTIBIOTIC
Generic Medical Partners Inc.
Date of Revision:
1500 Don Mills Road, Suite 406
October 26, 2020
Toronto, ON M3B 3K4
Control No.: 239577
2
PR
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP
ANTIBIOTIC
ACTIONS
The inhibition
of cell wall synthesis has been shown by _ in vitro _studies to be
responsible for the
bactericidal action of vancomycin against many gram-positive bacteria.
There is also evidence
that RNA synthesis is selectively inhibited
and the permeability of the cell membrane is altered
by vancomycin.
INDICATIONS AND CLINICAL USE
Vancomycin Hydrochloride
for Injection USP is indicated in the therapy of severe or life-
threatening staphylococcal infections in patients who cannot receive
or have failed to respond to
the penicillins or cephalosporins, or who have infections with
staphylococci resistant to other
antibiotics,
including methicillin.
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of
Vancomycin Hydrochloride
for Injection USP and other antibacterial drugs, Vancomycin
Hydrochloride for Injection USP should be used only to treat
infections that are proven or
strongly suspected to be caused by susceptible bacteria. When culture
and susceptibility
information
are available, they should be considered in selecting or modifying
antibacterial
therapy. In the absence of such data, local epidemiology
and susceptibility patterns may
contribute to the empiric selection of therapy.
In the treatment of staphylococcal endocarditis, vancomycin has been
used successfully alone.
In other infections due to staphylococci, including
osteomyelitis, pneumonia,
septicemia and soft-
tissue infections, vancomycin's effectiveness has been documented.
Antibiotics are used as
adjuncts to appropriate surgical measures when staphylococcal
infections are localized and
purulen